HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Nuvectis Pharma (NASDAQ:NVCT) and maintained a $21 price target.
September 15, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nuvectis Pharma's stock may see positive movement due to the reiterated 'Buy' rating and maintained $21 price target by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiterated 'Buy' rating and maintained $21 price target by HC Wainwright & Co. indicates their positive outlook on Nuvectis Pharma, which could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100